Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Purpose: The availability of novel imaging modalities (NIM) in prostate cancer (PCa) has overtaken the evidence informing their use. The recent EORTC consensus statement on modern imaging recognises the need for large-scale clinical trials of novel imaging [1].
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
